Twist Bioscience Corporation (TWST) Identifies Competitive Antibodies for SARS-CoV-2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Twist Bioscience Corporation (TWST) Misses Q2 EPS by 10c, Revenues Beat
May 7, 2020 4:59 PM EDTTwist Bioscience Corporation (NASDAQ: TWST) reported Q2 EPS of ($0.85), $0.10 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $19.3 million versus the consensus estimate of $18.27 million.
In the midst of the global pandemic, we introduced our methylation product for next-generation... More
